NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis $2.68 +0.25 (+10.29%) Closing price 04:10 PM EasternExtended Trading$2.59 -0.09 (-3.51%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Armata Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.45▼$2.6850-Day Range$1.84▼$2.7152-Week Range$0.90▼$2.96Volume14,985 shsAverage Volume104,729 shsMarket Capitalization$97.10 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Read More Armata Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreARMP MarketRank™: Armata Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArmata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArmata Pharmaceuticals has received no research coverage in the past 90 days.Read more about Armata Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.47% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently decreased by 24.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.47% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently decreased by 24.85%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.89 News SentimentArmata Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.57% of the stock of Armata Pharmaceuticals is held by institutions.Read more about Armata Pharmaceuticals' insider trading history. Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARMP Stock News HeadlinesArmata Pharmaceuticals Q3 EPS Boosted by HC WainwrightAugust 17, 2025 | americanbankingnews.comArmata Pharmaceuticals files $100M mixed securities shelfAugust 14, 2025 | msn.com"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That's why we've rushed to update our book "Crypto Revolution" – to show you exactly how to position yourself for this historic opportunity.August 22 at 2:00 AM | Crypto 101 Media (Ad)Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate UpdateAugust 13, 2025 | finanznachrichten.deArmata Pharmaceuticals Secures $15M Loan for DevelopmentAugust 12, 2025 | msn.comArmata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate UpdateAugust 12, 2025 | prnewswire.comArmata Pharmaceuticals Inc.July 3, 2025 | barrons.comArmata Pharmaceuticals Insider Trading Activity | AMEX:ARMP | BenzingaMay 20, 2025 | benzinga.comSee More Headlines ARMP Stock Analysis - Frequently Asked Questions How have ARMP shares performed this year? Armata Pharmaceuticals' stock was trading at $2.00 on January 1st, 2025. Since then, ARMP shares have increased by 27.0% and is now trading at $2.54. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) released its earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.02. The company had revenue of $1.23 million for the quarter, compared to the consensus estimate of $0.90 million. Who are Armata Pharmaceuticals' major shareholders? Top institutional shareholders of Armata Pharmaceuticals include GSB Wealth Management LLC (0.08%). View institutional ownership trends. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN). Company Calendar Last Earnings11/14/2023Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:ARMP CIK921114 Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees70Year FoundedN/APrice Target and Rating Average Price Target for Armata Pharmaceuticals$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+268.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.92 million Net Margins-374.30% Pretax Margin-374.30% Return on EquityN/A Return on Assets-24.00% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual Sales$5.17 million Price / Sales17.13 Cash FlowN/A Price / Cash FlowN/A Book Value($1.92) per share Price / Book-1.27Miscellaneous Outstanding Shares36,230,000Free Float5,616,000Market Cap$88.58 million OptionableNot Optionable Beta0.99 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSEAMERICAN:ARMP) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.